Literature DB >> 28839583

Cryptogenic colitis due to occult cytomegalovirus infection.

Daniel J B Marks1,2, Philip J Smith1,2, Farooq Z Rahman1,2, Robert F Miller3, Jonathan A Ledermann4, Stuart L Bloom2.   

Abstract

Colitis secondary to cytomegalovirus infection is well recognised and usually straightforward to diagnose. Here two cases are reported in whom all initial investigations failed to demonstrate the presence of virus, with potential adverse consequences for its treatment. A case is made for empirical antiviral therapy despite negative investigations if clinical suspicion is high.

Entities:  

Year:  2010        PMID： 28839583      PMCID： PMC5517193          DOI： 10.1136/fg.2010.001990

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  21 in total

1.  Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.

Authors:  Stephanie A S Staras; Sheila C Dollard; Kay W Radford; W Dana Flanders; Robert F Pass; Michael J Cannon
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

Review 2.  Ganciclovir.

Authors:  C S Crumpacker
Journal:  N Engl J Med       Date:  1996-09-05       Impact factor: 91.245

Review 3.  Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts.

Authors:  Polymnia Galiatsatos; Ian Shrier; Esther Lamoureux; Andrew Szilagyi
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

4.  Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

Authors:  Carlos V Paya; Jennie A Wilson; Mark J Espy; Irene G Sia; Michael J DeBernardi; Thomas F Smith; Robin Patel; Greg Jenkins; William S Harmsen; David J Vanness; Russell H Wiesner
Journal:  J Infect Dis       Date:  2002-03-19       Impact factor: 5.226

Review 5.  Antiviral treatment of cytomegalovirus infection and resistant strains.

Authors:  Andreas Schreiber; Georg Härter; Axel Schubert; Donald Bunjes; Thomas Mertens; Detlef Michel
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

6.  Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.

Authors:  Loreto Hierro; Ruth Díez-Dorado; Carmen Díaz; Angela De la Vega; Esteban Frauca; Carmen Camarena; Gema Muñoz-Bartolo; Ana González de Zárate; Manuel López Santamaría; Paloma Jara
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

7.  Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U.

Authors:  M H St Clair; W H Miller; R L Miller; C U Lambe; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.

Authors:  C Venturi; J Bueno; J Gavalda; T Tórtola; L Pou; A Medina; G Codina; R Charco; A Pahissa
Journal:  Transplant Proc       Date:  2009-04       Impact factor: 1.066

9.  Cytomegalovirus colitis in HIV-1-infected patients: a prospective research in 55 patients.

Authors:  H Mentec; C Leport; J Leport; C Marche; M Harzic; J L Vildé
Journal:  AIDS       Date:  1994-04       Impact factor: 4.177

10.  Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.

Authors:  B J Terry; K E Mazina; A V Tuomari; M L Haffey; M Hagen; A Feldman; W A Slusarchyk; M G Young; R Zahler; A K Field
Journal:  Antiviral Res       Date:  1988-12-01       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.